GLP-1 and Alzheimer’s, Eli Lilly, Takeda, FDA: Readout Publication
Wish to keep on prime of the science and politics driving biotech right this moment? Join to get our biotech publication in your inbox.
Morning! We’re closing in on CMS’s deadline for 2027 Medicare-negotiated drug costs. Plus, we see a break from precedent in how the FDA selects precedence evaluate vouchers, and extra.
Can a GLP-1 drug gradual Alzheimer’s illness? Nope
Novo Nordisk stated this morning {that a} pair of huge, placebo-controlled scientific trials testing an oral model of its GLP-1 drug semaglutide did not gradual the cognitive decline of individuals with Alzheimer’s illness.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
